Using GLP-1 Receptor Agonist to Reduce Heart Injury After Non-cardiac Surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of a single subcutaneous dose of Dulaglutide, a GLP-1 receptor agonist, in reducing myocardial injury in patients undergoing elective non-cardiac surgery. A total of 372 patients will be randomly assigned to receive either the medication or routine care, with assessments including cardiac evaluations and troponin level measurements to determine the drug's efficacy. The study aims to address the significant risk of myocardial injury, which is a leading cause of complications and mortality in the post-operative period. By evaluating the safety and effectiveness of this prophylactic approach, the trial seeks to provide new insights into managing peri-operative cardiovascular risks.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* Planned elective intermediate to high risk non-cardiac surgery
* Anticipated to remain hospitalized for at least one night after surgery
* Voluntarily agrees to participate by providing written informed consent

Exclusion Criteria:

* History of symptomatic hypoglycemia within 1 month of recruitment
* History of pancreatitis
* Diabetic retinopathy
* Personal or family history of medullary thyroid carcinoma (MTC)
* Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
* Acute coronary syndrome, decompensated heart failure, cardiogenic shock, or myocarditis within 1 month of recruitment
* Stroke or transient ischemic attack within 1 month of recruitment
* Known severe liver disease (Child-Pugh B or C)
* Stage 5 chronic kidney disease (estimated glomerular filtration rate (eGFR) by Modified Diet in Renal Disease (MDRD) equation \< 15 mL/min)
* Recent use of GLP-1 RA within 1 month of recruitment
* Known allergy or hypersensitivity to GLP-1 RA
* Women of childbearing age who are not taking effective contraception, or who are pregnant or breast-feeding
* Use of Dipeptidyl peptidase-4 inhibitor(DPP4i)

Where it's running

• Queen Mary Hospital
  Hong Kong, Hong Kong SAR, China Recruiting
• Tung Wah Hospital
  Hong Kong, Hong Kong SAR, China Recruiting
• Duchess of Kent Children's Hospital at Sandy Bay
  Hong Kong, Hong Kong SAR, China Not yet recruiting

Study contacts

• Principal investigator: Chun Ka Wong, Clinical Assistant Professor — The University of Hong Kong
• Study coordinator: Chun Ka Wong, Clinical Assistant Professor
• Email: wongeck@hku.hk
• Phone: +852 2255 3597

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding heart artery disease using biomarkers and imaging in Oxford

  Researchers in Oxford are testing how biomarkers and advanced imaging can help explain why some heart artery plaques are unstable and how this affects heart damage after a heart attack.

  Recruiting University of Oxford · Oxford · NCT07772570

• Ciprofol to reduce heart injury after VATS lung surgery

  This trial tests whether using ciprofol instead of propofol during general anesthesia for adults having VATS lung or mediastinal surgery can lower the chance of postoperative heart injury (MINS).

  Recruiting Phase 4 Tongji Hospital · Wuhan · NCT07028593

• Predicting heart transplant outcomes using donor heart biopsies

  This study is testing if looking at tissue samples from donor hearts can help predict how well the transplanted hearts will work and if they'll be rejected by the recipient's body.

  Recruiting Medical University of Vienna · Vienna, State of Vienna · NCT06982404

• Understanding the connection between stroke and heart issues

  This study is trying to understand how strokes affect heart health and overall well-being in stroke patients to find new ways to help them recover better.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT06954103

• Treatment for heart failure using patients' own fat-derived cells

  This study is testing whether injecting patients' own fat cells can improve heart function in people with chronic heart failure compared to those getting standard medical treatment.

  Recruiting Phase 2 ISAR Klinikum · Astana · NCT06705023

• Using colchicine to reduce heart risks in patients having major non-heart surgery

  This study is testing if colchicine can help lower heart risks for patients having major surgeries that aren't related to the heart.

  Recruiting Phase 3 Cantonal Hospital of St. Gallen · Sankt Gallen, Canton of St. Gallen · NCT06279000

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.